ID
21867
Description
Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC); ODM derived from: https://clinicaltrials.gov/show/NCT00609401
Link
https://clinicaltrials.gov/show/NCT00609401
Keywords
Versions (1)
- 5/4/17 5/4/17 -
Uploaded on
May 4, 2017
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Metastatic Disease NCT00609401
Eligibility Metastatic Disease NCT00609401
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
Therapeutic procedure Metastatic Renal Cell Cancer
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0087111
- UMLS CUI [1,2]
- C0278678
Description
Metastatic malignant neoplasm to brain | Compression of spinal cord
Data type
boolean
Alias
- UMLS CUI [1]
- C0220650
- UMLS CUI [2]
- C0037926
Description
Adrenal Cortex Hormones chronic
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0001617
- UMLS CUI [1,2]
- C0205191
Description
Uncontrolled hypertension
Data type
boolean
Alias
- UMLS CUI [1]
- C1868885
Similar models
Eligibility Metastatic Disease NCT00609401
- StudyEvent: Eligibility
C0278678 (UMLS CUI [1,2])
C0037926 (UMLS CUI [2])
C0205191 (UMLS CUI [1,2])